{"nctId":"NCT00528606","briefTitle":"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture","startDateStruct":{"date":"2007-08","type":"ACTUAL"},"conditions":["Dupuytren's Contracture"],"count":308,"armGroups":[{"label":"AA4500 0.58 mg","type":"EXPERIMENTAL","interventionNames":["Biological: collagenase clostridium histolyticum"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"collagenase clostridium histolyticum","otherNames":["XIAFLEX®","AA4500"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a diagnosis of Dupuytren's contracture, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100°, for MP (80° for PIP) joints, caused by a palpable cord that had never been treated with AA4500.\n* Had a positive \"table top test,\" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.\n* Judged to be in good health.\n\nExclusion Criteria:\n\n* Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.\n* Had received a treatment for Dupuytren's contracture, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study drug.\n* Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection","description":"The Primary Outcome Measure for patients treated with AA4500 is the percentage of joints that were successfully treated where \"successfully treated\" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection.\n\nThe Primary Outcome Measure for placebo treated patients is the percentage of joints that were successfully treated where \"successfully treated\" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement After the Last Injection","description":"Clinical Improvement is defined as \\>= 50% reduction from baseline in degree of contracture within 30 days of the injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.7","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture After the Last Injection","description":"Percent change in degree of contracture measured as 100\\* (baseline contracture - last available post-injection contracture)/baseline contracture.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":"32.58"},{"groupId":"OG001","value":"8.6","spread":"30.78"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion After the Last Injection","description":"Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.70","spread":"21.01"},{"groupId":"OG001","value":"4.0","spread":"14.77"}]}]}]},{"type":"SECONDARY","title":"Time to First Achieve Success After the Last Injection","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":null},{"groupId":"OG001","value":"93.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Success (Reduction in Contracture to 5° or Less) After the First Injection","description":"Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement After the First Injection","description":"Clinical Improvement is defined as \\>= 50% reduction from contracture within 30 days of the first injectionor greater of baseline contracture within 30 days of the injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture After the First Injection","description":"Percent change in degree of contracture measured as 100\\* (baseline contracture - last available post-injection contracture)/baseline contracture.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.8","spread":"34.60"},{"groupId":"OG001","value":"4.7","spread":"20.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion After the First Injection","description":"Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.30","spread":"20.23"},{"groupId":"OG001","value":"1.50","spread":"11.03"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":204},"commonTop":["Oedema peripheral","Contusion","Injection site haemorrhage","Injection site pain","Pain in extremity"]}}}